Basic Stats
| LEI | 5493007NPB5YRM8QGL53 |
| CIK | 1008848 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Acorda Therapeutics, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-31938 ACORDA THERAPEUTICS, INC. (Exact name of registrant as specified i |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
S-8 POS 1 s-8pos333-131846.htm S-8 POS As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. 333-131846 Registration No. 333-149726 Registration No. 333-158085 Registration No. 333-164626 Registration No. 333-174785 Registration No. 333-179906 Registration No. 333-187091 Registration No. 333-194375 Registration No. 333-202525 Registration No. 333-206346 Registrati |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
Exhibit 99.1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK In re Chapter 11 ACORDA THERAPEUTICS, INC., et al.,1 Case No. 24-22284 (DSJ) Debtors. Jointly Administered FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER (I) CONFIRMING THE MODIFIED FIRST AMENDED JOINT CHAPTER 11 PLAN OF LIQUIDATION OF ACORDA THERAPEUTICS, INC. AND ITS AFFILIATED DEBTORS AND (II) GRANTING RELATED RELIEF WHE |
|
| August 9, 2024 |
S-8 POS 1 s-8pos333-187091.htm S-8 POS As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. 333-131846 Registration No. 333-149726 Registration No. 333-158085 Registration No. 333-164626 Registration No. 333-174785 Registration No. 333-179906 Registration No. 333-187091 Registration No. 333-194375 Registration No. 333-202525 Registration No. 333-206346 Registrati |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
S-8 POS 1 s-8pos333-233177.htm S-8 POS As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. 333-131846 Registration No. 333-149726 Registration No. 333-158085 Registration No. 333-164626 Registration No. 333-174785 Registration No. 333-179906 Registration No. 333-187091 Registration No. 333-194375 Registration No. 333-202525 Registration No. 333-206346 Registrati |
|
| August 9, 2024 |
POS AM 1 posam333-239519.htm POS AM As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. 333-143348 Registration No. 333-147163 Registration No. 333-235929 Registration No. 333-239519 Registration No. 333-248728 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 POST EFFECTIVE AMENDMENT NO. 1 TO form s-3 registration statement no. 33 |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
S-8 POS 1 s-8pos333-210813.htm S-8 POS As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. 333-131846 Registration No. 333-149726 Registration No. 333-158085 Registration No. 333-164626 Registration No. 333-174785 Registration No. 333-179906 Registration No. 333-187091 Registration No. 333-194375 Registration No. 333-202525 Registration No. 333-206346 Registrati |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| August 9, 2024 |
S-8 POS 1 s-8pos333-149726.htm S-8 POS As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. 333-131846 Registration No. 333-149726 Registration No. 333-158085 Registration No. 333-164626 Registration No. 333-174785 Registration No. 333-179906 Registration No. 333-187091 Registration No. 333-194375 Registration No. 333-202525 Registration No. 333-206346 Registrati |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. |
|
| July 23, 2024 |
Exhibit 99.1 UNITED STATES BANKRUPTCY COURT Southern DISTRICT OF New York In Re. Acorda Therapeutics, Inc. Debtor(s) § § § § Case No. 24-22284 Lead Case No. 24-22284 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 06/30/2024 Petition Date: 04/01/2024 Months Pending: 3 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Emp |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 25, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 25, 2024 |
Exhibit 99.1 UNITED STATES BANKRUPTCY COURT Southern DISTRICT OF New York In Re. Acorda Therapeutics, Inc. Debtor(s) Case No. 24-22284 Lead Case No. 24-22284 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2024 Months Pending: 2 Reporting Method: Accrual Basis Debtor's Full-Time Employees (current): Debtor's Full-Time Employees (as of date of order for relief |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 24, 2024 |
Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT Southern DISTRICT OF New York In Re. Acorda Therapeutics, Inc. Debtor(s) § § § § Case No. 24-22284 Lead Case No. 24-22284 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 04/30/2024 Petition Date: 04/01/2024 Months Pending: 1 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Ca |
|
| May 24, 2024 |
☒ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, |
|
| April 29, 2024 |
Acorda Therapeutics, Inc. Incentive Compensation Clawback Policy Exhibit 97 Acorda Therapeutics, Inc. Compensation Clawback Policy Adopted July 27, 2023 1. Purpose The Board of Directors (the “Board”) of Acorda Therapeutics, Inc. (the “Company”) believes that it is in the best interest of the Company and its stockholders to maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s compensation philosophy. The Board has th |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA T |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 17, 2024 |
Acorda Therapeutics Announces Delisting from Nasdaq Exhibit 99.1 CONTACT: Tierney Saccavino [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Delisting from Nasdaq PEARL RIVER, N.Y. – April 15, 2024 – Acorda Therapeutics, Inc. today announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the Company’s failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 03, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 4, 2024 |
Acorda Therapeutics Announces Nasdaq Delisting Notification Exhibit 99.1 CONTACT: Tierney Saccavino [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Nasdaq Delisting Notification PEARL RIVER, N.Y. – April 3, 2024 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of busin |
|
| April 2, 2024 |
Exhibit 99.1 CONTACT: Acorda Therapeutics Tierney Saccavino [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement Acorda Files for Voluntary Chapter 11 Protection to Facilitate Orderly Sale Acorda Enters into a Restructuring Support Agreement with over 90% of the Secured Convertible Noteholders Patient Access to INBRI |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 1, 2024 |
List of Subsidiaries of the Registrant. Exhibit 21 List of Subsidiaries of the Registrant Acorda Therapeutics Limited (UK) Acorda Therapeutics Ireland Limited (Ireland) Biotie Therapies AG (Switzerland) Biotie Therapies, LLC. |
|
| April 1, 2024 |
Exhibit 10.48 Execution Version ASSET PURCHASE AGREEMENT BY AND AMONG ACORDA THERAPEUTICS, INC., CIVITAS THERAPEUTICS, INC., MERZ PHARMACEUTICALS, LLC and Merz Pharma GmbH & Co. KGaA (solely for the purposes set forth herein) Dated as of March 31, 2024 TABLE OF CONTENTS Page Article I THE ACQUISITION 2 Section 1.1 Acquired Assets 2 Section 1.2 Excluded Assets 4 Section 1.3 Assumed Liabilities 5 Se |
|
| April 1, 2024 |
Exhibit 4.1 DESCRIPTION OF COMMON STOCK We are a corporation formed under the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”) pursuant to our Certificate of Incorporation, as amended and restated on June 2, 2023 (the “Certificate of Incorporation”). The following is a description of the material terms of our common stock. This description does not purport |
|
| April 1, 2024 |
Exhibit 10.49 Execution Version THIS RESTRUCTURING SUPPORT AGREEMENT IS NOT AN OFFER OR ACCEPTANCE WITH RESPECT TO ANY SECURITIES OR A SOLICITATION OF ACCEPTANCES OF A CHAPTER 11 PLAN WITHIN THE MEANING OF SECTION 1125 OF THE BANKRUPTCY CODE. ANY SUCH OFFER OR SOLICITATION WILL COMPLY WITH ALL APPLICABLE SECURITIES LAWS AND/OR PROVISIONS OF THE BANKRUPTCY CODE. NOTHING CONTAINED IN THIS RESTRUCTUR |
|
| April 1, 2024 |
Form of Amendment to Employment Offer Letter, dated March 26, 2024 Exhibit 10.21 March 26, 2024 [] [Address] [City, State, Zip Code] Re: Amendment to Letter Agreement Dear Neil: This AMENDMENT TO LETTER AGREEMENT (this “Amendment”) is made and entered into on March 26, 2024 (“Effective Date”) by and between [] (“Executive”) and Acorda Therapeutics, Inc., for itself and its parents, subsidiaries and affiliates (“Employer” or “Company”). WHEREAS, the Company and Ex |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ldeFutue pr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPE |
|
| April 1, 2024 |
Form of Debtor-in-Possession Credit Agreement Exhibit 10.50 DEBTOR-IN-POSSESSION CREDIT AGREEMENT Dated as of April [], 2024 Among ACORDA THERAPEUTICS, INC., as Borrower and as Debtor and Debtor-in-Possession, THE LENDERS PARTY HERETO and GLAS USA LLC, as Administrative Agent and GLAS Americas LLC, as Collateral Agent TABLE OF CONTENTS Page Article I DEFINITIONS AND ACCOUNTING TERMS Section 1.01 Defined Terms 2 Section 1.02 Other Interpretive |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 13, 2024 |
Amended and Restated By-Laws of Acorda Therapeutics, Inc., effective March 7, 2024. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ACORDA THERAPEUTICS, INC. ARTICLE I STOCKHOLDERS 1.1 Place of Meetings. All meetings of stockholders shall be held at such place as may be designated from time to time by the Board of Directors, the Chairman of the Board or the Chief Executive Officer or, if not so designated, at the principal office of the corporation. The Board of Directors may, in its |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 11, 2024 |
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025 Exhibit 99.1 CONTACT: Acorda Therapeutics Tierney Saccavino [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025 PEARL RIVER, N.Y.– January 11, 2024 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it will regain global commercialization rights to FAMPYRA®(fampridine) following a decision by Biogen to termin |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTI |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 13, 2023 |
Acorda Therapeutics Reports Third Quarter 2023 Financial Results Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports Third Quarter 2023 Financial Results • INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 • AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 • INBRIJA ex-U.S. revenue of $1.4 milli |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q we UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS |
|
| August 8, 2023 |
Acorda Therapeutics Reports Second Quarter 2023 Financial Results Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports Second Quarter 2023 Financial Results • INBRIJA® (levodopa inhalation powder) Q2 2023 U.S. net revenue of $8.3 million, a 12% increase from Q2 2022; ex-U.S. net revenue of $0.8 million • New INBRIJA prescription request forms increased 42% in 1H 2023 over 2022 • AMPYRA® (d |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 26, 2023 |
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement PEARL RIVER, NY – June 26, 2023 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained com |
|
| June 2, 2023 |
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split PEARL RIVER, NY – June 2, 2023 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock. The |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 02, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 2, 2023 |
Amended and Restated Certificate of Incorporation of Acorda Therapeutics, Inc., dated June 2, 2023. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACORDA THERAPEUTICS, INC. Pursuant to Section 242 and 245 of the General Corporation Law of the State of Delaware Acorda Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: The name of the corporation (the “Corpora |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 31, 2023 |
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split PEARL RIVER, NY – May 31, 2023 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will conduct a reverse stock split of its outstanding and authorized shares of common stock at a ratio of 1-for-20. The reverse stock split wil |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
Acorda Therapeutics Reports First Quarter 2023 Financial Results Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports First Quarter 2023 Financial Results • INBRIJA® (levodopa inhalation powder) Q1 2023 U.S. net revenue of $5.6 million, a 52% increase from Q1 2022; ex-U.S. net revenue of $0.5 million • AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q1 2023 net revenue of $12.6 mi |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 10, 2023 |
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash PEARL RIVER, NY – May 10, 2023 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will make a cash interest payment of approximately $6.2 million due on June 1, 2023 under its Convertible Senio |
|
| May 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Acorda Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00484M601 (CUSIP Number) Shulamit Leviant, Esq. c/o Davidson Kempner Capital Management LP 520 Madison Avenue, 30th Floor New York, New York 10022 (212 |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2023 |
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China Exhibit 99.1 CONTACT: Acorda Therapeutics Tierney Saccavino [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China PEARL RIVER, N.Y.– May 08, 2023 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreeme |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14 INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confiden |
|
| April 27, 2023 |
DEFA14A 1 acor-2023-defa14a-no.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14 INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate bo |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 15, 2023 |
Exhibit 10.56 CONFIDENTIALEXECUTION VERSION Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks [*****]. FIRST AMENDMENT TO MANUFACTURING SERVICES AGREEMENT THIS FIRST AMENDMENT to the MANUFACTURING SERVIC |
|
| March 15, 2023 |
Exhibit 10.55 CONFIDENTIAL AGREEMENT EXECUTION VERSION Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks [*****].Manufacturing Services Agreement between Catalent Massachusetts LLC and Acorda Therapeutic |
|
| March 15, 2023 |
Exhibit 10.54 EXECUTION VERSION Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks [*****]. SETTLEMENT AND RELEASE AGREEMENT This Settlement and Release Agreement (the “Settlement Agreement”) is made as o |
|
| March 15, 2023 |
Exhibit 10.57 CONFIDENTIAL EXECUTION VERSION Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks [*****]. March 6, 2023 Catalent Massachusetts LLC 14 Schoolhouse Road Somerset, NJ 08873 Attn: Ricky Hopson |
|
| March 15, 2023 |
Exhibit 10.53 Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks [*****]. Manufacturing Services Agreement September 30, 2010 Doc #: 924418.1 Table of Contents ARTICLE 1 1 INTERPRETATION 1 1.1 Definitions |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Future pr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUT |
|
| March 15, 2023 |
List of Subsidiaries of the Registrant. Exhibit 21 List of Subsidiaries of the Registrant Acorda Therapeutics Limited (UK) Acorda Therapeutics Ireland Limited (Ireland) Biotie Therapies AG (Switzerland) Biotie Therapies GmbH (Germany) Biotie Therapies, Inc. |
|
| March 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Acorda Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00484M601 (CUSIP Number) Shulamit Leviant, Esq. c/o Davidson Kempner Capital Management LP 520 Madison Avenue, 30th Floor New York, New York 10022 (212 |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 9, 2023 |
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results EX-99.1 Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results • INBRIJA® (levodopa inhalation powder) 2022 U.S. net revenue of $28.0MM and ex-U.S. net revenue of $2.9MM; Q4 2022 U.S. net revenue of $9.0MM • AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg 2022 net rev |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 15, 2023 |
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement PEARL RIVER, NY – February 14, 2023 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Nasdaq Hearings Panel has granted the Company’s extension request until June 20, 2023 to regain compliance with t |
|
| February 14, 2023 |
SC 13G/A 1 acora421423.htm CANYON CAPITAL ADVISORS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Acorda Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 00484M601 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appro |
|
| January 23, 2023 |
SC 13D/A 1 p23-0335sc13da.htm ACORDA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acorda Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00484M601 (CUSIP Number) Shulamit Leviant, Esq. c/o Davidson Kempner Capital Management LP 520 |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 5, 2023 |
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA® EX-99.1 2 d441257dex991.htm EX-99.1 Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA® • Significant reduction in minimum purchase requirements • 2026 manufacturing capacity expansion expected to result in further reductions in cost of goods PEARL RIVER, |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 22, 2022 |
Acorda Therapeutics Announces Revised Long-Term Financial Guidance EX-99.1 2 d421861dex991.htm EX-99.1 Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Revised Long-Term Financial Guidance PEARL RIVER, NY – December 22, 2022 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 21, 2022 |
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing PEARL RIVER, NY ? December 20, 2022 ? Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the Compa |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 5, 2022 |
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash PEARL RIVER, NY ? December 5, 2022 ? Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 14, 2022 |
EX-99.1 Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders PEARL RIVER, NY – November 11, 2022 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company’s stockholders approved the Reverse Stock Split proposal at its reconven |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTI |
|
| November 7, 2022 |
DEFA14A 1 d306439ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| November 4, 2022 |
EX-99.1 Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders Scheduled to Reconvene November 11, 2022 at 9:00 a.m. Eastern Time at the Company’s Headquarters to Vote on Proposal Two PEARL RIVER, NY – November 4, 2022 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) convened its Spec |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 1, 2022 |
Acorda Therapeutics Reports Third Quarter 2022 Financial Results Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports Third Quarter 2022 Financial Results ? INBRIJA? (levodopa inhalation powder) Q3 2022 U.S. net revenue of $7.8 million; 1% increase over Q3 2021 ? AMPYRA? (dalfampridine) Q3 2022 net revenue of $21.1 million; 5% increase over Q3 2021 ? $16.5M award and royalty/supply relief |
|
| October 31, 2022 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| October 31, 2022 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| October 28, 2022 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 to CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdicti |
|
| October 28, 2022 |
EX-99.1 Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Corrected Press Release Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance • CEO video / Q&A with shareholders on October 28, 2022 to review business plan and ballot items for special meeting of stockholders PEARL RIVER, NY. – October 27, 2022 – Acorda Therapeutics, I |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 to CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of In |
|
| October 27, 2022 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 27, 2022 |
Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance EX-99.1 Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance • CEO video / Q&A with shareholders on October 28, 2022 to review business plan and ballot items for special meeting of stockholders PEARL RIVER, NY. – October 27, 2022 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| October 25, 2022 |
DEFA14A 1 d306439ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| October 25, 2022 |
DEFA14A 1 d306439ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| October 25, 2022 |
DEFA14A 1 d306439ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| October 24, 2022 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| October 21, 2022 |
DEFA14A 1 d306439ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 19, 2022 |
DEFA14A 1 d606403ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| October 19, 2022 |
Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE ISS, Glass Lewis and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split PEARL RIVER, NY. ? October 19, 2022 ? Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the three leading, independent proxy advisory firms?Institutional Shareholder |
|
| October 19, 2022 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| October 19, 2022 |
DEFA14A 1 d414487ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other J |
|
| October 18, 2022 |
EX-99.1 Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt PEARL RIVER, NY. – October 18, 2022 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will not use its common stock to make the approximately $6.2 million interest payment |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 17, 2022 |
Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case EX-99.1 Exhibit 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case • $16.5 million to recover past royalties and interest • Cessation of double-digit royalty/supply payments PEARL RIVER, NY. – October 16, 2022 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today anno |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| October 11, 2022 |
Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders PEARL RIVER, NY. ? October 10, 2022 ? Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the company has withdrawn Proposal One, a request to increase the number of authorized shares o |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 11, 2022 |
DEFA14A 1 d185280ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| October 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| October 3, 2022 |
DEFA14A 1 d400799ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| September 22, 2022 |
DEF 14A 1 d375370ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| September 12, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| August 30, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 30, 2022 |
Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals PEARL RIVER, N.Y. ? August 29, 2022 ? Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a bio |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 19, 2022 |
Acorda Therapeutics Announces Resignation of Chief Operating Officer Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Resignation of Chief Operating Officer PEARL RIVER, N.Y. ? August 19, 2022 ? Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a |
|
| August 16, 2022 |
As filed with the Securities and Exchange Commission on August 16, 2022 As filed with the Securities and Exchange Commission on August 16, 2022 Registration No. |
|
| August 16, 2022 |
Exhibit 4.7 ACORDA THERAPEUTICS, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN As amended June 10, 2022 Section 1. Purpose The purpose of the Acorda Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan (the ?Plan?) is to provide an additional incentive to directors, officers, employees, consultants, advisors and other service providers of Acorda Therapeutics, Inc. (the ?Company?) and its su |
|
| August 16, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Acorda Therapeutics, Inc. |
|
| August 9, 2022 |
Employment letter agreement, dated June 2, 2022, by and between the Registrant and Neil S. Belloff. Exhibit 10.5 June 2, 2022 Neil S. Belloff [Address] [City, State, Zip Code] Dear Neil: We are delighted to present this letter agreement (?Agreement?), setting out the terms of your continued employment with Acorda Therapeutics, Inc. (the "Company") as General Counsel. If these terms are acceptable, please sign and date the copy of this letter provided herewith and return it to me at your first co |
|
| August 9, 2022 |
Exhibit 10.3 June 2, 2022 Kerry Clem [Address] [City, State, Zip Code] Dear Kerry: I refer to the employment letter agreement (?Agreement?) effective as of September 1, 2020 (the ?Effective Date?), setting forth the terms of your employment with Acorda Therapeutics, Inc. (the "Company"). This letter agreement sets forth proposed amended and restated terms of your Agreement. Upon your signing, dati |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, I |
|
| August 9, 2022 |
Exhibit 10.2 June 2, 2022 Lauren Sabella [Address] [City, State, Zip Code] Dear Lauren: I refer to the employment letter agreement (?Agreement?) effective as of June 8, 2015 (the ?Effective Date?), as amended by a letter agreement dated January 6, 2022 (the ?Amendment?), setting forth the terms of your employment with Acorda Therapeutics, Inc. (the "Company"). This letter agreement sets forth prop |
|
| August 9, 2022 |
Employment letter agreement, dated June 2, 2022, by and between the Registrant and Michael Gesser. Exhibit 10.4 June 2, 2022 Michael A. Gesser [Address] [City, State, Zip Code] Dear Michael: We are delighted to present this letter agreement (?Agreement?), setting out the terms of your continued employment with Acorda Therapeutics, Inc. (the "Company") as Chief Financial Officer. If these terms are acceptable, please sign and date the copy of this letter provided herewith and return it to me at |
|
| August 4, 2022 |
Acorda Therapeutics Reports Second Quarter 2022 Financial Results EX-99.1 2 acor-ex99117.htm PRESS RELEASE Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports Second Quarter 2022 Financial Results • INBRIJA® (levodopa inhalation powder) Q2 2022 U.S. net revenue of $7.4 million; 16% increase from Q2 2021; 100% increase over Q1 2022 • Ex-U.S. INBRIJA Q2 additional revenue of $1.9 million • |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 24, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acorda Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00484M601 (CUSIP Number) June 2, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to |
|
| June 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. [])* Acorda Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00484M601 (CUSIP Number) Shulamit Leviant, Esq. c/o Davidson Kempner Capital Management LP 520 Madison Avenue, 30th Floor New York, New York 10022 (212) |
|
| June 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 16, 2022 |
Acorda Therapeutics Reports First Quarter 2022 Financial Results EX-99.1 2 acor-ex9917.htm PRESS RELEASE Exhibit 99.1 CONTACT: Tierney Saccavino [email protected] FOR IMMEDIATE RELEASE Corrected Press Release Acorda Therapeutics Reports First Quarter 2022 Financial Results • INBRIJA® (levodopa inhalation powder) Q1 2022 net revenue of $3.7 million; 26% decrease from Q1 2021 • AMPYRA® (dalfampridine) Q1 2022 net revenue of $14.9 million; 27% decrease from Q1 |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 to CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorp |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, |
|
| May 11, 2022 |
Acorda Therapeutics Reports First Quarter 2022 Financial Results EX-99.1 2 acor-ex99115.htm PRESS RELEASE EARNINGS Exhibit 99.1 CONTACT: Tierney Saccavino [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports First Quarter 2022 Financial Results • INBRIJA® (levodopa inhalation powder) Q1 2022 net revenue of $3.7 million; 26% decrease from Q1 2021 • AMPYRA® (dalfampridine) Q1 2022 net revenue of $14.9 million; 27% decrease from Q1 2021 • 2022 A |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2022 |
Exhibit 99.2 CONTACT: Tierney Saccavino [email protected] Biopas Laboratories Tommy Laine [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA? in Latin America ARDSLEY, N.Y. and PANAMA CITY, PANAMA ? May 11, 2022 ? Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Biopas Laboratories today announced that they have ente |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 18, 2022 |
Exhibit 10.25 Master CONSULTING AGREEMENT This Master Consulting Agreement (?Agreement?) is entered into as of January 1, 2022 (?Effective Date?) by and between Acorda Therapeutics, Inc., a Delaware corporation with offices at 420 Saw Mill River Road, Ardsley, NY 10502 (?Acorda?) and Burkhard Blank, M.D. residing at [address] (?Consultant?). Each of Acorda and Consultant are sometimes hereinafter |
|
| March 18, 2022 |
Exhibit 10.52 Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks [*****]. EXECUTION VERSION CONFIDENTIAL SECOND AMENDMENT TO MANUFACTURING SERVICES AGREEMENT THIS SECOND AMENDMENT to the MANUFACTURING SER |
|
| March 18, 2022 |
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Corrected Press Release Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results ? AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg 2021 net revenue of $84.6 million ? AMPYRA Q4 2021 net revenue of $22.5 million ? INBRIJA? (levodopa inhalation powder) 2021 net revenue of |
|
| March 18, 2022 |
Exhibit 10.10 ACORDA THERAPEUTICS, INC. 2016 INDUCEMENT Plan Section 1. Purpose The purpose of the Acorda Therapeutics, Inc. 2016 Inducement Plan (the ?Plan?) is to provide equity compensation to certain individuals who were not previously employees or directors of Acorda Therapeutics, Inc. (the ?Company?) or its Subsidiaries in order to induce such individuals to enter into employment with the Co |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Future pr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUT |
|
| March 18, 2022 |
Exhibit 10.11 Option Number: [] Shares ACORDA THERAPEUTICS, INC. 2016 Inducement Plan Non-Statutory Stock Option Certificate Acorda Therapeutics, Inc. (the ?Company?), a Delaware corporation, hereby grants to the person named below an option to purchase shares of Common Stock, par value $0.001 per share, of the Company (the ?Option?) under and subject to the Company?s 2016 Inducement Plan (the ?Pl |
|
| March 18, 2022 |
Exhibit 10.21 January 6, 2022 Ms. Lauren Sabella [Address] [City, State, Zip Code] Dear Lauren: This letter agreement amends the Employment Agreement between you and Acorda Therapeutics, Inc. (the "Company") dated as of June 8, 2015 (the ?Employment Agreement?). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Employment Agreement. This letter agreem |
|
| March 18, 2022 |
Exhibit 10.27 November 4, 2021 Michael A. Gesser [Address] [City, State, Zip Code] Dear Michael: I am pleased to confirm your employment as Chief Financial Officer reporting to Ron Cohen, President & CEO. The terms of the offer are as follows: 1. The salary is $450,000.00 per annum, payable semi-monthly on the 15th and the last business day of the month. The semi-monthly rate is $18,750.00. 2. You |
|
| March 18, 2022 |
List of Subsidiaries of the Registrant. Exhibit 21 List of Subsidiaries of the Registrant Acorda Therapeutics Limited (UK) Acorda Therapeutics Ireland Limited (Ireland) Biotie Therapies AG (Switzerland) Biotie Therapies GmbH (Germany) Biotie Therapies, Inc. |
|
| March 18, 2022 |
Exhibit 10.51 Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks [*****]. CONFIDENTIAL FIRST AMENDMENT TO MANUFACTURING SERVICES AGREEMENT THIS FIRST AMENDMENT to the MANUFACTURING SERVICES AGREEMENT (the |
|
| March 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 to CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incor |
|
| March 18, 2022 |
Exhibit 10.24 December 31, 2021 Burkhard Blank [Address] [City, State, Zip Code] RE:SEPARATION AGREEMENT AND GENERAL RELEASE Dear Burkhard, This letter (the ?Agreement?) confirms that your employment with Acorda Therapeutics, Inc. (the "Company" or ?Acorda?) will terminate effective the close of business, December 31, 2021 (the ?Effective Date?), and you will have no further job responsibilities a |
|
| March 18, 2022 |
Exhibit 10.28 November 4, 2021 Neil S. Belloff [Address] [City, State, Zip Code] Dear Neil: I am pleased to confirm your employment as General Counsel reporting to Ron Cohen, President & CEO. The terms of the offer are as follows: 1. The salary is $450,000.00 per annum, payable semi-monthly on the 15th and the last business day of the month. The semi-monthly rate is $18,750.00. 2. Your start date |
|
| March 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 9, 2022 |
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results ? AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg 2021 net revenue of $84.6 million ? AMPYRA Q4 2021 net revenue of $22.5 million ? INBRIJA? (levodopa inhalation powder) 2021 net revenue of $29.6 million; 22% incr |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 to CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of I |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Acorda Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.0 |
|
| February 14, 2022 |
ACOR / Acorda Therapeutics Inc / UBS OCONNOR LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Acorda Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00484M601** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Acorda Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 00484M601 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 6, 2022 |
John Varian Joins Acorda Therapeutics Board of Directors Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE John Varian Joins Acorda Therapeutics Board of Directors ARDSLEY, N.Y. ? January 3, 2022 ? Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that John Varian has joined its board of directors, effective January 1, 2022. ?We are delighted that John has joined Acorda?s board of directors,? said |
|
| December 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTI |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 9, 2021 |
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany EX-99.2 3 acor-ex99216.htm PRESS RELEASE EXHIBIT 99.2 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany • €5 million upfront payment • Significant double-digit percent of selling price for supply • Additional sales-based milestones • Commercial launch expected mid-2022 ARDSLEY, N.Y. – N |
|
| November 9, 2021 |
Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team EXHIBIT 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team ? INBRIJA? (levodopa inhalation powder) Q3 2021 net revenue of $7.8 million; 34% increase over Q3 2020 ? AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg Q3 2021 net revenue of $20.0 million ? Agreem |
|
| September 21, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 9, 2021 |
Acorda Therapeutics Announces Corporate Restructuring, Management Changes EX-99.1 3 acor-ex99143.htm PRESS RELEASE Exhibit 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Corporate Restructuring, Management Changes • 15% reduction in headcount • Greater than $20 million in expected annualized cost savings from headcount and budget reductions ARDSLEY, N.Y. – September 09, 2021 – Acorda Therapeutics, |
|
| September 9, 2021 |
EXHIBIT 10.1 September 1, 2020 Kerry Clem 1106 Pinebury Court Bel Air, MD 21015 Dear Kerry: We are delighted to present this letter agreement (?Agreement?), setting out the terms of your continued employment with Acorda Therapeutics, Inc. (the "Company") as Executive Vice President, Sales, Market Access and Operations. If these terms are acceptable, please sign and date the copy of this letter pro |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, I |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 5, 2021 |
Acorda Therapeutics Reports Second Quarter 2021 Financial Results EXHIBIT 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports Second Quarter 2021 Financial Results ? INBRIJA? (levodopa inhalation powder) Q2 2021 net revenue of $6.4 million; 36% increase over Q2 2020 ? AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg Q2 2021 net revenue of $21.8 million ? Agreement to commercialize INBRIJA |
|
| July 23, 2021 |
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain EXHIBIT 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Agreement to Commercialize INBRIJA? in Spain ARDSLEY, N.Y. ? July 22, 2021 ? Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A (ESTEVE) to commercialize INBRIJA? 33 mg (lev |
|
| July 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 16, 2021 |
Acorda Therapeutics Announces Repayment of Convertible Senior Notes EX-99.1 2 acor-ex99115.htm EX-99.1 EXHIBIT 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Repayment of Convertible Senior Notes ARDSLEY, N.Y. – June 16, 2021 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that on June 15, 2021, it repaid in full its 1.75% Convertible Senior Notes due 2021. Prior to their maturity |
|
| June 4, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 14, 2021 |
DEFA14A 1 acor-defa14a20210602.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| May 12, 2021 |
EXHIBIT 10.2 May 12, 2021 Mr. Robert Morales 18 Brothers Road Poughquag, NY 12570 Subject: Acorda Change in Control Severance Policy (Vice President) (the ?Policy?) Dear Rob: I am writing in regards to the Policy (a copy is attached for reference), which is applicable to you as an Acorda Vice President. The purpose of this letter is to confirm Acorda?s agreement, due to the additional responsibili |
|
| May 12, 2021 |
EXHIBIT 10.1 Restricted Stock Unit Number: RESTRICTED STOCK UNIT AGREEMENT This Agreement is entered into as of , by and between ACORDA THERAPEUTICS, INC., a Delaware corporation (?Company?), and the stated Employee referenced below. Name of Employee: Address: Number of Shares: WITNESSETH: NOW, THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable conside |
|
| May 12, 2021 |
Acorda Therapeutics, Inc. Directors Compensation Policy, as amended April 15, 2021. EXHIBIT 10.3 ACORDA THERAPEUTICS, INC. DIRECTORS COMPENSATION POLICY 1. Overview This Policy shall govern compensation for non-employee Directors (?Outside Directors?) of the Board of Directors (the ?Board?) of Acorda Therapeutics, Inc. (the ?Company?). Compensation for Outside Directors shall consist of both cash and equity components, in order to align their interests with those of the Company?s |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 6, 2021 |
Acorda Therapeutics Reports First Quarter 2021 Financial Results EX-99.1 2 acor-ex99149.htm EX-99.1 EXHIBIT 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Reports First Quarter 2021 Financial Results • INBRIJA® (levodopa inhalation powder) Q1 2021 net revenue of $5 million; 13% increase over Q1 2020 • INBRIJA organic growth (dispensed cartons) was 25% Q1 2021 over Q1 2020 • AMPYRA® (dalfampridine) |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Acorda Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 00484M601 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| April 23, 2021 |
DEF 14A 1 acor-def14a20210602.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| March 16, 2021 |
Exhibit 10.49 Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks [*****]. ASSET PURCHASE AGREEMENT by and between ACORDA THERAPEUTICS, INC. and CATALENT PHARMA SOLUTIONS, INC. Dated as of January 12, 2021 |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, INC. |
|
| March 16, 2021 |
Exhibit 10.50 EXECUTION COPY Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks [*****]. Manufacturing Services Agreement between Catalent Massachusetts LLC and Acorda Therapeutics, Inc. Dated February 10 |
|
| March 16, 2021 |
Exhibit 4.1 COMMON STOCK $0.001 PAR VALUE PER SHARE Certificate Number ZQ00000000 THIS CERTIFIES THAT is the owner of COMMON STOCK Shares 000000 000000 000000 000000 000000 000000 ACORDA THERAPEUTICS ACORDA THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE MR SAMPLE & MRS SAMPLES & MR SAMPLE & MRS SAMPLE ***ZERO HUNDRED THOUSAND ZERO HUNDRED ZERO*** SEE REVERSE FOR CERTAIN DE |
|
| March 16, 2021 |
List of Subsidiaries of the Registrant. Exhibit 21 List of Subsidiaries of the Registrant Acorda Therapeutics Limited (UK) Acorda Therapeutics Ireland Limited (Ireland) Biotie Therapies AG (Switzerland) Biotie Therapies GmbH (Germany) Biotie Therapies, Inc. |
|
| March 16, 2021 |
Exhibit 4.2 DESCRIPTION OF COMMON STOCK We are a corporation formed under the General Corporation Law of the State of Delaware (the ?Delaware General Corporation Law?) pursuant to our Amended and Restated Certificate of Incorporation, as further amended through December 31, 2020 (the ?Certificate of Incorporation?). The following is a description of the material terms of our common stock. This des |
|
| March 4, 2021 |
EXHIBIT 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results • Sale of Manufacturing Operations to Catalent with net proceeds of ~$74 million • Annual operating expenses cut by ~$40 million via sale, restructuring, and other reductions • Total 2021 non- |
|
| March 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 19, 2021 |
Acorda Therapeutics Announces Departure of Chief, Business Operations EX-99.1 2 acor-ex9918.htm EX-99.1 EXHIBIT 99.1 CONTACT: Tierney Saccavino (914) 326-5104 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Departure of Chief, Business Operations ARDSLEY, N.Y. – February 19, 2021 – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that David Lawrence, Chief, Business Operations and its principal accounting and financial officer, is r |
|
| February 17, 2021 |
Acorda Therapeutics, Inc. Unaudited Pro Forma Condensed Consolidation Financial Statements EXHIBIT 99.2 Acorda Therapeutics, Inc. Unaudited Pro Forma Condensed Consolidation Financial Statements Introduction On January 12, 2021 Acorda Therapeutics, Inc. (the ?Company?) and Catalent Pharma Solutions, Inc. (?Catalent?) entered into an asset purchase agreement (the ?Asset Purchase Agreement?), pursuant to which the Company agreed to sell to Catalent certain assets related to the Company?s |
|
| February 17, 2021 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 17, 2021 |
Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent EX-99.1 2 acor-ex99129.htm EX-99.1 EXHIBIT 99.1 CONTACT: Tierney Saccavino (917) 783-0251 [email protected] FOR IMMEDIATE RELEASE Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent ARDSLEY, NY – February 11, 2021 - Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the sale of its manufacturing operations in Chelsea, Massachuset |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acorda Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 00484M601 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acorda Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 00484M106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 16, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Acorda Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.0 |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* Acorda Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00484M106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 10, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) ACORDA THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00484M601 (CUSIP Number) January 31, 2021 (Date of Event Which Requires Filing of t |
|
| February 10, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) ACORDA THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00484M601 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of t |
|
| January 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021 Acorda Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-31938 13-3831168 (State or Other Jurisdiction of Incorporation) (Commiss |
